Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of shareholding changes within an employee retirement plan and does not contain financial performance data.
Material Changes
The filing details two specific movements in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") involving Ordinary Share ADRs:
- October 6, 2006: The number of ADRs held by the fund increased from 17,381,918 to 17,425,711 at an average price of $53.95.
- October 12, 2006: The number of ADRs held by the fund decreased from 17,425,711 to 17,412,629 at an average price of $54.31.
These changes were notified to the company on October 9 and October 16, 2006, respectively.
Management Commentary and Risks
The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, two directors, Dr. J-P Garnier and Dr. M M Slaoui, are potentially interested in the shares held in the fund in the same manner as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b). No other risks, contingencies, or unusual items are discussed in this filing.
Investor Verification Points
- Verify the total aggregate holdings of the GlaxoSmithKline US Retirement Savings Plan to understand the scale of the reported movements.
- Confirm the specific beneficial ownership interests of Directors Dr. J-P Garnier and Dr. M M Slaoui within the discretionary fund.
- Review the company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial metrics.